DHODH

DGAP-News: Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer

Thursday, October 14, 2021 - 12:08pm

NEW YORK, October 14, 2021 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced the appointment of Patrick Walsh as Chief Business Officer, effective today.

Key Points: 
  • NEW YORK, October 14, 2021 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced the appointment of Patrick Walsh as Chief Business Officer, effective today.
  • "Patrick is a seasoned business development executive who has spent his career helping to successfully build a number of public biopharmaceutical companies.
  • He brings to Immunic extensive leadership in building companies through strategic partnerships and non-dilutive funding," stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic.
  • Mr. Walsh was previously in Corporate Development at AVEO Oncology, during which time he worked on all aspects of business development.

Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer

Thursday, October 14, 2021 - 11:30am

In this newly created role, Mr. Walsh will be responsible for business development, including strategic partnering opportunities, and will become part of the executive management team of Immunic.

Key Points: 
  • In this newly created role, Mr. Walsh will be responsible for business development, including strategic partnering opportunities, and will become part of the executive management team of Immunic.
  • "Patrick is a seasoned business development executive who has spent his career helping to successfully build a number of public biopharmaceutical companies.
  • He brings to Immunic extensive leadership in building companies through strategic partnerships and non-dilutive funding," stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic.
  • Mr. Walsh was previously in Corporate Development at AVEO Oncology, during which time he worked on all aspects of business development.

DGAP-News: Immunic, Inc. Enrolls First Patient in Its Phase 2 CALLIPER Trial of IMU-838 in Progressive Multiple Sclerosis

Thursday, September 30, 2021 - 12:08pm

The trial, which is intended to run concurrently with and as a complement to the company's twin phase 3 ENSURE trials in relapsing-remitting multiple sclerosis (RRMS), is focused on progressive forms of multiple sclerosis (MS) and designed to corroborate IMU-838's neuroprotective potential in this patient population.

Key Points: 
  • The trial, which is intended to run concurrently with and as a complement to the company's twin phase 3 ENSURE trials in relapsing-remitting multiple sclerosis (RRMS), is focused on progressive forms of multiple sclerosis (MS) and designed to corroborate IMU-838's neuroprotective potential in this patient population.
  • If the CALLIPER trial is successful in showing beneficial data, we believe this could be an essential differentiator for IMU-838 in the MS market."
  • Multiple sclerosis (MS) is an autoimmune disease that affects the brain, spinal cord and optic nerve.
  • Progressive multiple sclerosis (PMS) includes both primary progressive MS (PPMS) and secondary progressive MS (SPMS).

DGAP-News: Immunic, Inc. to Participate in Scientific and Investor Conferences in October

Tuesday, September 28, 2021 - 12:08pm

Three abstracts have been accepted for presentation, including a late-breaker on the company's lead asset IMU-838.

Key Points: 
  • Three abstracts have been accepted for presentation, including a late-breaker on the company's lead asset IMU-838.
  • Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will participate in a fireside chat.
  • Members of Immunic's business development and investor relations teams will participate in partnering activities at this conference.
  • Examples of such statements include, but are not limited to, statements relating to management's participation in scientific and investor conferences.

Immunic, Inc. to Participate in Scientific and Investor Conferences in October

Tuesday, September 28, 2021 - 11:30am

The poster presentations will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .

Key Points: 
  • The poster presentations will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .
  • Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will participate in a fireside chat.
  • Members of Immunic's business development and investor relations teams will participate in partnering activities at this conference.
  • Examples of such statements include, but are not limited to, statements relating to management's participation in scientific and investor conferences.

ASLAN Pharmaceuticals Announces Positive Data Conclusively Establishing Proof of Concept for ASLAN004 in Atopic Dermatitis

Monday, September 27, 2021 - 11:00am

ASLAN Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients.

Key Points: 
  • ASLAN Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients.
  • ASLAN is currently evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease.
  • The Phase 1 study was a multiple ascending dose study designed to deliver proof of concept and evaluated three doses of ASLAN004 (200mg, 400mg and 600mg) delivered subcutaneously compared to a placebo arm.
  • These statements are based on the current beliefs and expectations of the management of ASLAN Pharmaceuticals Limited and/or its affiliates (the "Company").

Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19

Wednesday, September 22, 2021 - 11:30am

In addition to molnupiravir, Immunic is exploring alternate nucleoside analogues, some of which have shown very promising antiviral activity in vitro.

Key Points: 
  • In addition to molnupiravir, Immunic is exploring alternate nucleoside analogues, some of which have shown very promising antiviral activity in vitro.
  • Matthias Dobbelstein, M.D., Professor of Molecular Oncology, University Medical Center Goettingen, added, "We are proud of the results of our preclinical work.
  • We were very pleased with this license agreement with Immunic and look forward to future results with these very promising combinations."
  • Although the technology in-licensed by Immunic includes the potential combination of DHODH inhibitors with nucleoside analogues, including molnupiravir, Immunic does not have any rights to molnupiravir itself.

DGAP-News: Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19

Wednesday, September 22, 2021 - 11:59am

Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19- Preclinical Combination Data Suggests Extra-Ordinary Synergy Between Certain DHODH Inhibitors and Nucleoside Analogues -- Combination of IMU-838 and N4-Hydroxycytidine Reduced SARS-CoV-2 Virus Levels, Including the Delta Variant, Down to the Detection Limit -NEW YORK and GOETTINGEN, Germany, September 22, 2021 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced the execution of an in-license agreement with the University Medical Center Goettingen, Germany, covering the combination of DHODH inhibitors and nucleoside analogues to treat viral infections (COVID-19 and Influenza). Terms of the agreement were not disclosed.
Preclinical research recently completed by the parties and their collaborators[1] has shown that certain DHODH inhibitors, including Immunic's lead asset, IMU-838, strongly synergize with selected nucleoside analogues to inhibit SARS-CoV-2 replication in vitro. For instance, in an in vitro test system, IMU-838 alone showed an up to 99.9% reduction in viral RNA at concentrations of 5 μM, which is well within the exposure levels seen in prior clinical trials. Likewise, N4-hydroxycytidine (NHC), the active metabolite of molnupiravir[2], alone, was associated with an up to 99% reduction in viral RNA at concentrations of 100 nM. Compared to single agent activity, the combination of IMU-838 and NHC achieved an extra-ordinary reduction in viral RNA, down to the limit of detection, reducing SARS-CoV-2 RNA by up to seven log units (corresponding to 0.00001% viral RNA remaining). This powerful reduction of virus replication in vitro was demonstrated across multiple SARS-CoV-2 variants, including alpha, beta and delta, highlighting the independence of this approach to mutant virus forms. In addition to molnupiravir, Immunic is exploring alternate nucleoside analogues, some of which have shown very promising antiviral activity in vitro. The company plans to present detailed data at an upcoming scientific conference.
"Research by the University Medical Center Goettingen and other research partners revealed a profound degree of synergy in vitro when combining certain nucleoside analogues with DHODH inhibitors, including both our lead asset IMU-838 and other of our preclinical molecules," stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic. "Recalling IMU-838's clinical activity against COVID-19 in our phase 2 CALVID-1 trial published earlier this year, and in light of recent exacerbations in COVID-19, worldwide, we are very excited to have in-licensed this technology to incorporate into our pandemic preparedness effort. However, with the extra-ordinary wealth of activity already ongoing at the company in other programs, we intend to evaluate and pursue the best possible strategic option for this program, including potential partnership, collaboration or external funding."

Key Points: 
  • Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19
    The issuer is solely responsible for the content of this announcement.
  • In addition to molnupiravir, Immunic is exploring alternate nucleoside analogues, some of which have shown very promising antiviral activity in vitro.
  • Matthias Dobbelstein, M.D., Professor of Molecular Oncology, University Medical Center Goettingen, added, "We are proud of the results of our preclinical work.
  • Although the technology in-licensed by Immunic includes the potential combination of DHODH inhibitors with nucleoside analogues, including molnupiravir, Immunic does not have any rights to molnupiravir itself.

Rhizen Pharmaceuticals AG Announces First Patient Dosed in a Phase 2 Study of RP7214 in Covid-19 Patients

Tuesday, September 21, 2021 - 5:36pm

Rhizen Pharmaceuticals AG, a clinical-stage oncology & inflammation-focussed biopharmaceutical company, today announced that the first patient has been dosed in a Phase 2 clinical trial of RP7214, a small molecule oral dihydroorotate dehydrogenase (DHODH) Inhibitor.

Key Points: 
  • Rhizen Pharmaceuticals AG, a clinical-stage oncology & inflammation-focussed biopharmaceutical company, today announced that the first patient has been dosed in a Phase 2 clinical trial of RP7214, a small molecule oral dihydroorotate dehydrogenase (DHODH) Inhibitor.
  • Viral replication involves a huge demand for building blocks and relies on nucleotides derived from host cells.
  • Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology & inflammation therapeutics.
  • Beyond this, Rhizen has a deep oncology & inflammation pipeline spanning discovery to Phase 2 clinical development stages.

F2G appoints Camilla Soenderby to Board of Directors

Wednesday, September 15, 2021 - 8:00am

MANCHESTER, England, PRINCETON, N.J.and VIENNA, Sept. 15, 2021 /PRNewswire/ -- F2G Ltd, a clinical-stage biopharmaceutical company focused on rare life-threatening fungal diseases with a high unmet medical need, today announces the appointment of Camilla Soenderby as a Non-Executive Director to its Board of Directors with immediate effect.

Key Points: 
  • MANCHESTER, England, PRINCETON, N.J.and VIENNA, Sept. 15, 2021 /PRNewswire/ -- F2G Ltd, a clinical-stage biopharmaceutical company focused on rare life-threatening fungal diseases with a high unmet medical need, today announces the appointment of Camilla Soenderby as a Non-Executive Director to its Board of Directors with immediate effect.
  • Patrick Vink, Chairman of F2G Ltd, said: "On behalf of the whole board I am very pleased to welcome Camilla to F2G.
  • Camilla began her career as a management consultant at McKinsey & Co. focused on the biopharmaceutical and medical devices industries.
  • F2G is a world-leading biotech company focused on the discovery and development of novel therapies to treat life-threatening invasive fungal infections.